atezolizumab + tiragolumab + carboplatin + paclitaxel

**Atezolizumab + tiragolumab + carboplatin + paclitaxel** is a four-drug combination regimen under clinical investigation, primarily for the treatment of advanced solid tumors such as non-small cell lung cancer. \n- **Atezolizumab** is a monoclonal antibody that inhibits PD-L1, blocking immune checkpoint pathways and enhancing antitumor immune response[2][5][6]. \n- **Tiragolumab** is a monoclonal antibody targeting TIGIT, another immune checkpoint, and is thought to further amplify the immune response when combined with PD-L1 blockade[1][2][5][7]. \n- **Carboplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing tumor cells. \n- **Paclitaxel** is a chemotherapy drug that stabilizes microtubules, inhibiting cell division and promoting cancer cell death. \nThis combination leverages immune checkpoint inhibition (atezolizumab, tiragolumab) alongside cytotoxic chemotherapy (carboplatin, paclitaxel) for a synergistic anticancer effect. The combo is being investigated by major pharmaceutical developers, especially for PD-L1 positive and immunotherapy-naïve cancers[1][5][7].

Brand names

Tecentriq (atezolizumab)Abraxane (paclitaxel, albumin-bound, if used; otherwise Paclitaxel generic)

Other names

atezolizumab + tiragolumab + carboplatin + paclitaxel